Juan Carlos Prieto

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome

J. Wouter Jukema, Michael Szarek, Laurien E. Zijlstra et al. · Journal of the American College of Cardiology · 2019 · 237 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Interaction of Vasoactive Intestinal Peptide with Isolated Intestinal Epithelial Cells from Rat

Juan Carlos Prieto, Marc Laburthe, G Rosselin · European Journal of Biochemistry · 1979 · 178 citations · Full text

Life Sciences, Cell Biology, Pharmacology +11

Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go

Tamara Dangouloff, Eva Vrščaj, Laurent Servais et al. · Neuromuscular Disorders · 2021 · 172 citations

Medicine, Pediatrics, Preventive Medicine +12

Expression of the transient receptor potential vanilloid 1 (TRPV1) in LNCaP and PC-3 prostate cancer cells and in human prostate tissue

María Gracia Sánchez‐Alonso, Ana M. Sánchez, Beatriz Collado et al. · European Journal of Pharmacology · 2005 · 130 citations

Life Sciences, Molecular Biology, Oncology +12